In December 2020, ACell was acquired by Integra LifeSciences, an integrated medical device company itself having been - albeit briefly - an SBIR funded firm. Previously located in Massachusetts, ACell Inc. is a regenerative medicine company developing tissue-engineered products that encourage the body's own response system to help repair damaged tissue. Fairly active in SBIR in its early years, ACell has been focused to expanding its position in the veterinary care field. Based on naturally occurring biological scaffolds, the tissue-engineered products produced by ACell change the fundamental healing response by encouraging the bodyâs own regenerative capabilities to repair tissues and restore them to natural health. The companyâs technology increases the breadth of treatment options for disease and injuries and has applicability in a wide variety of treatments including wound care, surgery, orthopedics, dermatology, and cardiovascular medicine. ACell markets, distributes, and sells its products both directly and through strategic partner
